Teladoc Health's chronic condition programs serve over 1 million active enrollees, utilizing connected devices, data-driven personalization, and expert coaching to promote lasting behavior changes and improve cardiometabolic health outcomes.
The company supports over 1 million enrollees in its chronic condition programs, using connected devices, personalized data, and expert coaching to improve cardiometabolic health.
Eligible Amazon customers can now discover and enroll in Teladoc's programs for diabetes, hypertension, pre-diabetes, and weight management through Amazon's Health Benefits Connector, previously known as Health Condition Programs.
Notably, over half of U.S. adults have a chronic condition, yet many face barriers to accessing digital health programs, the company said in the press release. Nearly 25% are unaware of their full health plan benefits.
Amazon's Health Benefits Connector addresses this by highlighting eligible benefits during product searches. Teladoc Health's participation reflects a joint effort to prioritize consumer-centric healthcare solutions.
Investors can gain exposure to the stock via KraneShares Trust KraneShares Man Buyout Beta Index ETF (NYSE:BUYO).
Teladoc Health Stock Prediction for 2025
Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
Price Action: TDOC shares are up 7.94% at $10.47 premarket at the last check Tuesday.
Read Next:
Photo: courtesy of Teladoc.
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Market News and Data brought to you by Benzinga APIs© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
